Ischemic Heart Disease
Conditions
Interventions
0.125 mg/kg of landiolol hydrochloride was injected for 60 s.
Sponsors
DELIGHT study group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The patient who has the necessity for the heart rate reduction by beta blocking agent medication with 80 bpm or less heart rate just before administration.
Exclusion criteria
Exclusion criteria: 1)Patients with an implantable cardiac pacemaker or an implantable cardioverter-defibrillator 2)Patients who was previously treated with coronary artery bypass grafting 3)Patients with cardiomyopathy 4)Patients with a valve disease 5)Patients with an advanced bradycardia (heart rate less than 50 bpm) 6)Patients with blood pressure less than 110 mmHg at the time into the CT room 7)Patients with atrial fibrillation or premature beat, and expected them during the CTA 8)Patients with contraindication of landiolol hydrochloride 9)Patients with contraindication of nonionic contrast media 10)Patients with relative contraindication of nonionic contrast media and examination doctor judged to be unsuitable for incorporating 11)Patients who had severe allergy experience 12)Patients under pregnancy and breast-feeding and with the possibility of pregnancy, or the patient who wishes to become pregnant during examination period 13)Patients who examination doctor judged to be unsuitable for incorporating because of another reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We compare exposed dose at CT angiography and the estimated exposure dose by the heart rate just before medication. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) exposed dose at CCTA 2) ratio of the patients who could use prospective gating mode at CT angiograph 3) heart rate, blood pressure 4) assessability of the CCTA 5) adverse events, side effect | — |
Countries
Japan
Contacts
Public ContactTeruhito Kido
Ehime University Graduate School of Medicine Department of Radiology
Outcome results
None listed